An Eiger BioPharmaceuticals drug being tested for the treatment of pulmonary arterial hypertension has failed a mid-stage study, and the drug developer says it will stop work on the compound for that condition.
News of the clinical trial failure cut the value of shares in Palo Alto, CA, based Eiger (NASDAQ: EIGR) nearly in half. The company’s stock price closed at $8.10 Tuesday, down 49.3 percent from last Friday’s closing price.
In pulmonary arterial hypertension (PAH), high blood pressure develops in the arteries that carry blood to the lungs. The condition leads to shortness of breath, chest pain, and fainting…. Read more »
UNDERWRITERS AND PARTNERS